Перейти к содержанию

Aptevo Therapeutics Inc. (APVO) stock: revenue, earnings & dividend

Aptevo Therapeutics Inc. (APVO, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener APVO · Nasdaq Pharma & Biotech US-WA

Key figures

Fiscal year
2025
Revenue
–
Revenue growth
–
Revenue growth 5y (p.a.)
–
Net income
-25.97 m $
Net margin
–
Operating margin
–
Earnings per share (diluted)
-87.27 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
27.2 m $
Equity
17.4 m $
Equity ratio
63.9 %
Return on equity
-149.4 %
Cash
21.6 m $
Operating cash flow
-25.59 m $
Free cash flow
–
Shares outstanding
1,801,970

History

Revenue by fiscal year

2016 9.99 m $
2017 14.7 m $
2018 23.1 m $
2019 32.4 m $
2020 4.31 m $
2021 12.3 m $
2022 3.11 m $

Net income by fiscal year

2016 -112.42 m $
2017 6.97 m $
2018 -53.69 m $
2019 -40.45 m $
2020 -17.75 m $
2021 -28.46 m $
2022 8.03 m $
2023 -17.41 m $
2024 -24.13 m $
2025 -25.97 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
2025–-25.97 m $-87.27 $–-25.59 m $
2024–-24.13 m $-31,460.23 $–-23.79 m $
2023–-17.41 m $-2,316.83 $–-11.73 m $
20223.11 m $8.03 m $1.57 $–-21.02 m $
202112.3 m $-28.46 m $-6.07 $–-21.68 m $
20204.31 m $-17.75 m $––-29.32 m $
201932.4 m $-40.45 m $––-42.38 m $
201823.1 m $-53.69 m $––-51.42 m $
201714.7 m $6.97 m $––-41.57 m $
20169.99 m $-112.42 m $–––

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)